Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$11.72
-$0.14(-1.13%)
At close: 4:00 PM EST
$11.72
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $13.20
Previous CloseN/A
Volume175.11K
Average Volume (3M)2.41M
Market Cap
$1.21B
Enterprise Value$1.16B
Total Cash (Recent Filing)$451.58M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 24, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding105,704,636
10 Day Avg. Volume1,969,527
30 Day Avg. Volume2,411,655
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue8.70
Enterprise Value/Gross Profit9.73
Enterprise Value/Ebitda-8.21
Forecast
1Y Price Target
$22.29Price Target Upside90.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Durability And Re-treatmentExtended follow-up and re-treatment data showing sustained tumor reductions and recovery of growth velocity support broader clinician adoption of Ojemda in second-line pediatric low-grade glioma.
Commercial TractionAnalyst cites stronger-than-expected Ojemda sales and expanding new patient starts as evidence that commercial momentum could materially boost revenue growth.
Pipeline Expansion Via AcquisitionCompletion of the Mersana acquisition adds an antibody-drug conjugate platform, Emi-Le as a clinical asset targeting a rare cancer, and experienced development personnel, creating additional development and commercial opportunities.
Bears Say
Competitive And Regulatory Risk For Emi-LeMultiple peers developing similar B7-H4 targeted therapies and unclear timing for additional Emi-Le dosing data and regulatory interactions create competitive and development risk for the program.
Safety And Prescribing ConstraintsA notable share of patients experienced reversible decreases in growth velocity on Ojemda, which could lead clinicians to restrict use in some pediatric subgroups and limit market penetration.
Valuation Pressure From TransactionAnalyst notes the acquisition, while not changing intrinsic cash flow estimates, could depress the stock's trading multiple and weigh on near-term share performance.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $13.20 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $1.21B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Feb 24, 2026 which is in 13 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.107.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 105,704,636 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 25.205%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.29 (90.19% Upside)
$22.29 (90.19% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 878.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.79%
12-Months-Change
Fundamentals
Return on Equity
-30.16%
Trailing 12-Months
Asset Growth
-14.49%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, increased prescriptions, and positive clinical data. The raised revenue guidance and inclusion in NCCN guidelines further support a positive trajectory. However, the high gross-to-net ratio and limited impact of EAP patients were noted challenges.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$22.29
▲(90.19% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
1.60% Insiders
17.81% Mutual Funds
0.36% Other Institutional Investors
67.65% Public Companies and
Individual Investors